AnyTime News 
Confederation of Indian Industry (CII) in collaboration with Uttar Pradesh State Industrial Development Authority (UPSIDA) organized a Conference on Friday, 6 June in Ahmedabad on the theme “Investment Opportunities in Uttar Pradesh’s Pharmaceutical Landscape.” CII remains committed to working closely with the Uttar Pradesh government to attract investment and drive sustainable growth in the pharmaceutical sector.
The event aimed to inform investors about the immense potential of the pharmaceutical industry in Uttar Pradesh and invite them to explore business opportunities in the state. The event witnessed participation from key representatives of the pharmaceutical industry, investors, and policymakers.
*A New Era for Pharma in Uttar Pradesh*
Under the dynamic leadership of *Hon’ble Chief Minister Shri Yogi Adityanath* , UPSIDA has been making continuous strides toward strengthening the state’s industrial infrastructure. As part of the mission to make Uttar Pradesh a $1 trillion economy, UPSIDA is developing a Bulk Drug Pharma Park spread across 1,472.33 acres in the Lalitpur district, with a proposed investment of approximately ₹250 crore. This initiative is a significant step toward achieving self-reliance in the pharmaceutical sector and positioning India as the “Pharmacy of the World.”
This project will not only attract significant investment but also create new employment opportunities for the skilled workforce of the state. This Pharma Park is estimated to attract an investment of approximately ₹ 12000 crore, which will give a significant boost to the industrial landscape of the state. Additionally, this project is also expected to generate direct and indirect employment for around 14000 people, thereby strengthening the local economy.
The event commenced with the registration process, followed by a welcome address by *Mr. Swapnil Shah, Convenor of the CII Gujarat Pharma & Healthcare Panel and CEO & MD of Senores Pharmaceuticals Ltd.*
A short film showcasing Uttar Pradesh’s industrial growth, investor-friendly policies, and robust infrastructure was presented to give investors a comprehensive overview of the state’s potential.
In a special address, *UPSIDA CEO Mr. Mayur Maheshwari* emphasized the rapid development of pharma parks in Uttar Pradesh. He elaborated on the investment process, land allotment, and the range of facilities available to industries, extending a direct invitation to Gujarat-based entrepreneurs to invest in the state.
*Hon’ble Chief Minister’s Advisor, Dr. G.N. Singh* , in his address, stated that Uttar Pradesh is emerging as the most favourable state in India for pharmaceutical investments. He also shared detailed insights into the government’s ongoing efforts to strengthen the pharma sector.
An engaging ‘Open House’ session followed, where participants had the opportunity to directly interact with government officials, ask questions, and receive clarifications on industry-related matters.
The event concluded with a vote of thanks delivered by *Mr. Shanay Shah, President, Shalby Limited,* who appreciated the efforts of UPSIDA and CII in bridging industry and government for sustainable economic development.
Subsequently, Business-to-Government (B2G) meetings were held, facilitating in-depth discussions between industry representatives and government officials regarding investment prospects in the pharma sector. These interactions served as a crucial step toward understanding and addressing the needs of the pharmaceutical industry.
*Uttar Pradesh: A Leading Investment Destination*
*UPSIDA CEO, Mr. Mayur Maheshwari,* as the chief guest, presented Uttar Pradesh as a premier industrial destination and highlighted the state government’s investor-friendly policies. He remarked, “Uttar Pradesh is emerging as a major industrial hub of India. The state government is fully committed to providing comprehensive support to investors.”
*UPSIDA Signs Key Agreements with Pharma Companies in Ahmedabad*
During a high-level investment session held in Ahmedabad, the Uttar Pradesh State Industrial Development Authority (UPSIDA) signed several important Memorandums of Understanding (MoUs) with leading pharmaceutical and healthcare companies. This initiative marks a significant step toward strengthening the state’s industrial infrastructure and generating new employment opportunities for the youth of Uttar Pradesh.
*CSL Lifesciences Pvt. Ltd.* has proposed an investment of ₹200 crore (₹100 crore each for IV Bottle Plant and OSD Plant) on approximately 5–7 acres of land, which is expected to generate employment for over 250 people. The project is set to commence within the next two years.
*Mediheath Diagnostic Pvt. Ltd.* will establish a healthcare unit over 4,200 square meters in Lalitpur.
*Gaman Irradiation* plans to invest ₹35 crore in Lalitpur for setting up a Skin Treatment and Irradiation Unit, creating 150 jobs. The project will be implemented within 24 to 36 months.
Additionally, *Obmed Pharma* has committed an investment of ₹200 crore to set up a formulation unit on 5 acres of land in Lalitpur, which will provide employment to around 100 people. The project is expected to begin within the next two years.
UPSIDA will provide full support in terms of land allotment, approvals, and incentives to ensure the timely execution of these projects. These investments will play a pivotal role in realizing the vision of Hon’ble Chief Minister Yogi Adityanath to make Uttar Pradesh a $1 trillion economy.
*Invitation to Investors*
*Mr. Maheshwari* further stated that Uttar Pradesh offers investors top-notch logistics infrastructure, world-class industrial facilities, and highly conducive policies. This roadshow marks a significant initiative in promoting pharmaceutical investments and establishing Uttar Pradesh as a leading pharmaceutical hub in the country.
“The pharmaceutical sector is a key pillar of India’s economic growth, public health, and export capacity, and Uttar Pradesh is determined to become a national leader in this space,” he said.
Through this roadshow, UPSIDA not only highlighted the immense potential for pharmaceutical investment in the state but also assured investors of swift and transparent approvals, land allotment, and infrastructure support through a Single Window System.
